CONNECT WITH US
HealthTech

HealthTech

Galvanize raises $130M to advance pulsed electric field ablation

MedTech Dive logo

Published on

Add as a preferred source on Google
Galvanize raises $130M to advance pulsed electric field ablation

The Series D round will support commercialization of Galvanize’s soft-tissue ablation platform and development of a chronic bronchitis device.

PEF devices deliver high-frequency, short-duration energy to induce programmed cell death. By slowly killing cells and preserving the extracellular matrix, PEF may cause less damage to healthy tissue than other locally delivered ablative therapies.

Galvanize received 510(k) clearance for an earlier version of Aliya in 2022. Later that year, the company merged with Gala Therapeutics and Galaxy Medical to acquire the RheOx and Centauri platforms. Having raised $100 million at the time of the merger, Galvanize reeled in a further $100 million last year.

The latest financing round follows the FDA’s clearance of an updated version of Aliya and the first commercial uses of the system. The updated system enables physicians to create ablation zones of about 20 mm in diameter, as well as the 10 mm zones supported by the older device. Supporting larger ablation zones could increase the pool of patients eligible for PEF.

Galvanize is commercializing Aliya while working to bring its RheOx platform to the U.S. market. RheOx, which launched in Europe in 2022, delivers PEF energy to the lung airways to reduce mucus-producing cells in chronic bronchitis patients.

HealthQuest Capital led the Series D round. Olympus Innovation Ventures and Braidwell invested in the company for the first time. Existing investors, including Sofinnova Partners, Norwest and Elevage Medical Technologies, also participated in the round.

Garheng Kong, HealthQuest’s founder and managing partner, is joining Galvanize’s board of directors.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.